Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A et al (2016) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol 34:179–185

Article  CAS  PubMed  Google Scholar 

Petrelli F, Ardito R, Ghidini A, Zaniboni A, Ghidini M, Barni S (2018) Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis. Oncology 94:191–199

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

Article  PubMed  Google Scholar 

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065–1075

Article  CAS  PubMed  Google Scholar 

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705

Article  CAS  PubMed  Google Scholar 

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–4713

Article  CAS  PubMed  Google Scholar 

Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319

Article  CAS  PubMed  Google Scholar 

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664

Article  PubMed  Google Scholar 

Melosky B, Anderson H, Burkes RL, Chu Q, Hao D, Ho V et al (2016) Pan Canadian Rash Trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer. J Clin Oncol 34:810–815

Article  CAS  PubMed  Google Scholar 

Arrieta O, Vega-González MT, López-Macías D, Martínez-Hernández JN, Bacon-Fonseca L, Macedo-Pérez EO et al (2015) Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. Lung Cancer 88:282–288

Article  PubMed  Google Scholar 

Nakata K, Komori T, Saso K, Ota H, Kagawa Y, Morita S et al (2021) Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer. Int J Color Dis 36:2621–2627

Article  Google Scholar 

Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351–1357

Article  CAS  PubMed  Google Scholar 

Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I et al (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 11:617–627

Article  CAS  PubMed  Google Scholar 

Saito Y, Uchiyama K, Takekuma Y, Komatsu Y, Sugawara M (2023) Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment. Support Care Cancer 31:504

Article  PubMed  Google Scholar 

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345

Article  CAS  PubMed  Google Scholar 

Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1–17

Article  PubMed  Google Scholar 

Jatoi A, Green EM, Rowland KM, Sargent DJ, Alberts SR (2009) Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 77:120–123

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raimondi A, Fucà G, Leone AG, Lonardi S, Antoniotti C, Smiroldo V et al (2021) Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. ESMO Open 6:100246

Article  CAS  PubMed  PubMed Central  Google Scholar 

Annunziata MC, De Stefano A, Fabbrocini G, Leo S, Marchetti P, Romano MC et al (2019) Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer. Clin Drug Investig 39:825–834

Article  CAS  PubMed  Google Scholar 

Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P et al (2016) Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Oncologist 21:1483–1491

Article  CAS  PubMed  PubMed Central  Google Scholar 

Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT et al (2011) Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 22:524–535

Article  CAS  PubMed  Google Scholar 

Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V et al (2008) Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 26:1427–1434

Article  CAS  PubMed  Google Scholar 

Vallböhmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA et al (2005) Molecular determinants of cetuximab efficacy. J Clin Oncol 23:3536–3544

Article  PubMed  Google Scholar 

Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y et al (2015) Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Sci 106:604–610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi N, Yamada Y, Furuta K, Honma Y, Iwasa S, Takashima A et al (2014) Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer 110:2716–2727

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kubo A, Hashimoto H, Takahashi N, Yamada Y (2016) Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol 22:887–894

Article  CAS  PubMed  PubMed Central  Google Scholar